Literature DB >> 30149378

Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.

Dani A C Heesterbeek1, Mathieu L Angelier1, Richard A Harrison2, Suzan H M Rooijakkers3.   

Abstract

Complement is a complex protein network of plasma, and an integral part of the innate immune system. Complement activation results in the rapid clearance of bacteria by immune cells, and direct bacterial killing via large pore-forming complexes. Here we review important recent discoveries in the complement field, focusing on interactions relevant for the defense against bacteria. Understanding the molecular interplay between complement and bacteria is of great importance for future therapies for infectious and inflammatory diseases. Antibodies that support complement-dependent bacterial killing are of interest for the development of alternative therapies to treat infections with antibiotic-resistant bacteria. Furthermore, a variety of novel therapeutic complement inhibitors have been developed to prevent unwanted complement activation in autoimmune inflammatory diseases. A better understanding of how such inhibitors may increase the risk of bacterial infections is essential if such therapies are to be successful.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Antibiotic resistance; Antibody therapy; Bacteria; Complement; Eculizumab; Infections; Inflammatory diseases; Membrane attack complex; Neisseria

Mesh:

Substances:

Year:  2018        PMID: 30149378      PMCID: PMC6784045          DOI: 10.1159/000491439

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  89 in total

1.  Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

Authors:  B A Fernie-King; D J Seilly; C Willers; R Würzner; A Davies; P J Lachmann
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

3.  Structure of C3b reveals conformational changes that underlie complement activity.

Authors:  Bert J C Janssen; Agni Christodoulidou; Andrew McCarthy; John D Lambris; Piet Gros
Journal:  Nature       Date:  2006-10-15       Impact factor: 49.962

Review 4.  Complement driven by conformational changes.

Authors:  Piet Gros; Fin J Milder; Bert J C Janssen
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

5.  Meningococcal sepsis complicating eculizumab treatment despite prior vaccination.

Authors:  G H Struijk; A H M Bouts; G T Rijkers; E A C Kuin; I J M ten Berge; F J Bemelman
Journal:  Am J Transplant       Date:  2013-01-07       Impact factor: 8.086

6.  Dual-Track Clearance of Circulating Bacteria Balances Rapid Restoration of Blood Sterility with Induction of Adaptive Immunity.

Authors:  Steven P Broadley; Ann Plaumann; Raffaele Coletti; Christin Lehmann; Andreas Wanisch; Amelie Seidlmeier; Knud Esser; Shanshan Luo; Patrick C Rämer; Steffen Massberg; Dirk H Busch; Menno van Lookeren Campagne; Admar Verschoor
Journal:  Cell Host Microbe       Date:  2016-06-23       Impact factor: 21.023

7.  The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms.

Authors:  Catherine Hyams; Emilie Camberlein; Jonathan M Cohen; Katie Bax; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

8.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 9.  Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications.

Authors:  Brian V Geisbrecht
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

10.  Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Authors:  Suzan H M Rooijakkers; Jin Wu; Maartje Ruyken; Robert van Domselaar; Karel L Planken; Apostolia Tzekou; Daniel Ricklin; John D Lambris; Bert J C Janssen; Jos A G van Strijp; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more
  38 in total

1.  A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.

Authors:  Henrik Pedersen; Rasmus K Jensen; Annette G Hansen; Trine A F Gadeberg; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

2.  Erythrocyte Complement Receptor 1 Gene Polymorphisms and Neonatal Respiratory Distress Syndrome.

Authors:  Walaa Rabie; Ahmed Al-Taweel; Walaa A Abuelhamd; Walaa Shahin; Marian Nazeer; Hany Aly
Journal:  J Pediatr Genet       Date:  2020-10-05

Review 3.  More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion.

Authors:  Elisabet Bjanes; Victor Nizet
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-27       Impact factor: 11.056

4.  Orally administered β-glucan improves the hemolytic activity of the complement system in horses.

Authors:  Taline Scalco Picetti; Lucas de Figueiredo Soveral; Rovian Miotto; Luana Marina Scheer Erpen; Yasmin Kreutz; João Antônio Guizzo; Rafael Frandoloso; Luiz Carlos Kreutz
Journal:  Vet World       Date:  2021-04-05

5.  Priming With Toll-Like Receptor 3 Agonist Poly(I:C) Enhances Content of Innate Immune Defense Proteins but Not MicroRNAs in Human Mesenchymal Stem Cell-Derived Extracellular Vesicles.

Authors:  Lisa M Pierce; Wendy E Kurata
Journal:  Front Cell Dev Biol       Date:  2021-05-24

6.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.

Authors:  Michael Maes; Aristo Vojdani; Sunee Sirivichayakul; Decio S Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

Review 7.  Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens.

Authors:  Daniel V Zurawski; Molly K McLendon
Journal:  Antibiotics (Basel)       Date:  2020-04-01

Review 8.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

9.  Antibacterial Fusion Proteins Enhance Moraxella catarrhalis Killing.

Authors:  Maisem Laabei; Lucie Colineau; Serena Bettoni; Karolina Maziarz; David Ermert; Kristian Riesbeck; Sanjay Ram; Anna M Blom
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

Review 10.  Complement Activation as a Helping Hand for Inflammophilic Pathogens and Cancer.

Authors:  Marcin Okrój; Jan Potempa
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.